Group items matching

in title, tags, annotations or url

Elemental information and data relating to the clinical trials on Cholera and includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe.

The Royal Pharmaceutical Society (RPS) has called on employers, governments and NHS organisations to provide pharmacists with regular protected learning time (PLT) within working hours to develop their skills in clinical delivery, education, research and leadership. RPS workforce wellbeing survey showed an average 42 per cent of pharmacists were not given any PLT, a figure which rose to 55 per cent in community pharmacy. Most were unable to engage in professional development activities as part of their working day because of their responsibility to deliver frontline clinical services to patients. This means learning is often undertaken outside of working hours, increasing pressure on individuals and impacting their work/life balance. The survey showed that 48 per cent of respondents identified a lack of PLT as negatively affecting their mental health and wellbeing and that 88 per cent were at high risk of burnout. PLT improves the quality of patient care through professional practice and reflection, helping to develop insights, maintain and refine care standards and increase confidence. It facilitates continuous professional development (CPD), ensuring that skills and knowledge are up to date.

In a bid to amplify the role of pharmacists in clinical services and vaccination programs, the Pharmacists' Defence Association (PDA) has embarked on a groundbreaking collaboration with Aston University. This initiative, funded by Innovate UK Business Connect, aims to explore the feasibility and impact of integrating additional healthcare interventions within community pharmacies. "The Knowledge Transfer Partnership (KTP) research project represents an exciting opportunity to advance the role of pharmacists in patient care," remarked Alison Jones, Director of Policy at PDA. "This project will be an important part of that evolution, supporting individual pharmacists to have more opportunities to practice and so develop more fulfilling careers." Led by the PDA and Aston University, the project will commence imminently, focusing on the Priory Community Pharmacy in Dudley.

Pharmacy teams are being encouraged to support the ground-breaking Platform Adaptive trial of Novel antivirals for early treatment of Covid-19 In the Community (PANORAMIC) study by raising awareness among patients. The study aims to find out whether new antiviral treatments can help Covid-19 patients avoid hospital admission and support a quicker recovery. The PANORAMIC trial will allow researchers to gather data on the potential benefits of treatments to patients and will help the NHS to develop plans for rolling out the products to further patients in 2022. Anyone over the age of 50 or between 18 to 49 with certain underlying health conditions can participate in the trial after receiving a positive PCR or lateral flow test result for Covid-19. People who wish to participate in the trial can sign up themselves through the study's website and may be contacted by a member of the clinical team in a general practice that has been set up to deliver the PANORAMIC trial.

Developing a new medicine is a sophisticated and complex task which initially begins with the understanding of disease or condition as thoroughly as possible. At first, the researchers conduct studies in cells, tissues and animal models to determine whether the disease or condition can be influenced by new molecule.

The Association of the British Pharmaceutical Industry (ABPI) has proposed a Voluntary Scheme for Pricing, Access and Growth (VPAG) that aims to deliver a sustainable approach to medicines provision and maximise the growth potential of the UK life sciences industry. It has published the industry's vision for a new agreement with the government which will deliver for patients, the NHS and the economy. VPAG also includes measures to ensure rapid patient access and adoption of new medicines, as well as opportunities to improve health outcomes and productivity for the whole country. The association's proposals consist of four key areas: restoring an internationally competitive commercial environment for life sciences; supporting UK clinical research and R&D; ensuring rapid patient access and uptake of new medicines; and improving population health and productivity through health innovation. The proposal would deliver over £1bn a year to the NHS - around £300m more than the average delivered under the old scheme before 2023, and comfortably more than the highest contributions ever made before the pandemic.

The Association of the British Pharmaceutical Industry (ABPI) has laid out a series of urgent actions it wants the newly elected Labour government to implement within its first 100 days in office. Among the top priorities, the ABPI has emphasised the urgent need to appoint a new Chair and Chief Executive for the Medicines and Healthcare products Regulatory Agency (MHRA). Additionally, the ABPI has urged the new government to launch the Life Sciences Manufacturing Capital Grants Facility without delay. Other measures the ABPI wants Labour to prioritise include: Rapidly passing outstanding UK clinical trials legislation to enhance the UK's attractiveness for inward investment, including into research within the NHS. Increasing commercial flexibility in the NHS England Commercial Framework for New Medicines to remove barriers for companies to launch new medicines and indications so that NHS patients can access the latest innovative medicines.

One in eight people who were hospitalised with Covid-19 between May 2020 and March 2021 were later diagnosed with myocarditis, according to major new research into the clinical long-term effects of coronavirus. The largest study of its kind to date was led by the University of Glasgow in collaboration with NHS Greater Glasgow and Clyde (NHS GGC), and followed for one year, in real time, 159 patients after they were hospitalised with Covid-19. The study also looked at why some patients suffer long-term ill health after hospitalisation with Covid-19. Until now it has been speculated that previous underlying health conditions may be linked to the severity of post-Covid long-term effects. However, this new study suggests that it is the severity of the infection itself which is most closely correlated to the severity of a patient's long-Covid symptoms, rather than pre-existing health problems. Hospitalisation with Covid-19 was found to cause a number of long-term health problems. Researchers found one in eight patients hospitalised with Covid-19 have heart inflammation, while inflammation across the body and damage to the other organs such as the kidneys was also common.

When someone says erectile dysfunction, the first thing that you may think is of "Viagra" or similar drugs to revive your sex crusade. Even if established medics can assist, they induce side effects, which is why most men choose natural options. Besides, adverse effects of Viagra can result in back pain, memory issues, nausea, loss of hearing, and more. When shifting to natural remedies, you can improve your sexual version without giving the body a ridiculous amount of toxins and chemicals. Ginger, a root vegetable and one of the main ingredients in many traditional Asian dishes, has been used for centuries in conventional medications to treat various ailments. In recent years, ginger has received attention as an herbal remedy for sexual health problems such as erectile dysfunction (ED), premature ejaculation (PE), and infertility. It turns out that this ancient herb can be very effective at improving your sex life! How Does Ginger Benefits Male Sexually? Its potent medicinal combinations have made this natural treatment a focal point in investigations and comprehensive research over the years. Here is what makes ginger (zingiber officinale) a mighty sexual therapy. We've enclosed all the benefits it can suggest. But, nothing has gained more momentum than its impact on male sexual ability. 1. Ginger is an aphrodisiac and boosts sex drive. Ginger has been used as an aphrodisiac for centuries. An aphrodisiac is any food or medicine that stimulates sexual intuition, cajoles veneral craving, and boosts pleasure and performance. The spicy flavor of ginger can help increase your libido and has also been shown to improve erectile dysfunction and sexual performance in men. Aside from its role as an aphrodisiac, ginger is also a known sperm motility enhancer. In fact, according to clinical studies, just one gram of fresh ginger can improve sperm count by up to 35 percent! 2. It can improve sexual satisfaction. Ginger can also improve overall sexual satisfaction by

Imagine how far Medicine has taken the world. Just a few decades ago you hardly had medicines to cure the simplest of medical problems. Would you even believe that it wasn't until the late 1960s that Ibuprofen was invented? But now almost every issue you have can be solved with a pill, capsule or a simple visit to a specialist. This is all thanks to medical innovations brought about by intense research.

If you've steered clear of almonds for fear of excess calories, a new study may prompt you to reconsider the nutrient-dense nut. According to the findings of recent research published in the European Journal of Clinical Nutrition, people who added 1.5 ounces of almonds to their diet each day reported reduced hunger, and they compensated for the extra calories from nuts by eating less at other times of the day. Read the full article to know all the benefits of almonds and try the RECIPE!

Three leading pharmacists - professor Mahendra Patel, Asif Aziz and Ade Williams - have been recognised in Queen Elizabeth's annual New Year's honours list. Professor Patel, an academic pharmacist from West Yorkshire, was awarded an OBE for his "services to pharmacy." He told Pharmacy Business: "I am truly honoured and deeply humbled by this highly prestigious award that I have always believed was more deserving for others. "That's not to say I'm not proud of it - far from it, although for me it's not necessarily about rewards and recognition but more the intricacies of the journey I embark on and the learning and joy that those encounters bring with it. Most recently, Professor Patel - who has had a broad ranging portfolio career spanning community pharmacy, health education and health promotion, academia, and research - has been involved in promoting clinical trials across community pharmacies in the UK. His latest work has seen him act as one of the national leads for the PRINCIPLE and PANORAMIC trials, run by Oxford University - both trials seek to pioneer repurposed and new drug treatments in the community to prevent hospitalisation due to Covid-19.

Pharmacy professionals to be included as key stakeholders in the implementation, delivery and evaluation of a wide range of genomic services, said the Royal Pharmaceutical Society (RPS). RPS's statement has been developed in collaboration with pharmacy organisations who have co-badged the report, such as the British Oncology Pharmacy Association, the UK Clinical Pharmacy Association, Association of Pharmacy Technicians and the College of Mental Health Pharmacy. It looks at current and future roles for pharmacy professionals in genomic medicine across many aspects of practice such as person-centred care and collaboration, professional practice, education, leadership, management and research. Pharmacists and pharmacy technicians in the UK have already established roles in the application of genomic medicine in some areas of practice, such as antimicrobial stewardship and infectious diseases, and the management of certain genetic conditions, such as cystic fibrosis. The society believes, the current role of pharmacy professionals in genomics can be expanded upon in the future to both lead and support many relevant aspects of genomic implementation. These are described across all healthcare sectors, within the Genome UK strategy produced by the UK Government, and within the implementation plans published in England, Scotland and Wales. Lead for Pharmacogenomics at RPS Sophie Harding said: "Pharmacy professionals are the gatekeepers of medication safety and efficacy across all areas of healthcare. They are skilled at interpreting complex scientific data and use evidence-based medicine to maximise the benefits of treatments for patients, whilst supporting shared decision-making with patients and the multidisciplinary team.

Six pharmacists based in Scotland were acknowledged by the profession this week during a celebratory event held at the home of Scottish pharmacy, the RPS building on Melville Street, Edinburgh. Four pharmacists have been officially conferred with Fellowships of RPS for their significant contributions to the practice of pharmacy. The recipients are: Richard Lowrie Lynn Morrison Deborah Steven Audrey Thompson Two pharmacists, Katherine Davidson and Emily Kennedy, have attained accreditation as consultant pharmacists. This designation is granted in recognition of their demonstrated expertise at a senior level, spanning clinical practice, leadership, research, and education, RPS said in a statement.

Silver Diamine Fluoride 38% Caries Protecting Solution Caries Remover fagmin COMPOSITION : Silver diamine fluoride contains approximately 24-28 % (weight/volume) silver and 5-6 % (weight/volume) Research on the use of Silver Diamine Fluoride says exposure to one drop of SDF orally would result in less fluoride ion content than is present in a 0.25 mL topical treatment of fluoride varnish. The exact amount of silver and fluoride present in one drop of SDF is determined by the specific gravity of the liquid and the dropper used. The main disadvantage of SDF is its esthetic result (i.e., permanently blackens enamel and dentinal caries lesions and creates a temporary henna-appearing tattoo if allowed to come in contact with skin). Skin pigmentation is temporary since the silver does not penetrate the dermis Practical Applications in the following cases : High caries-risk patients with anterior or posterior active cavitated lesions havioral or medical management challenges Patients with multiple cavitated caries lesions that may not all be treated in one visit Difficult to treat cavitated dental caries lesions Patients without access to or with difficulty accessing dental care Active cavitated caries lesions with no clinical signs of pulp involvement.

The health secretary, Steve Barclay was asked over the delay of 'Pharmacy First' model in England that was proposed by the Pharmaceutical Services Negotiating Committee (PSNC) last year, at the Health Committee evidence session held on Tuesday (31 January). Taiwo Owatemi MP (Chair of the Pharmacy APPG) asked whether he was adhering to his statutory responsibility to ensure continued access to medicines and cited the CCA's closures in areas of deprivation research. Barclay replied that the government is 'investing more'. He said, "We put an extra 100 million on top of the 2.6 billion a year we commit to community pharmacy to expand the range of clinical services. We've got over 2 million patients that have been referred to community pharmacy from NHS." He further added: "One of the issues I'm very keen on is to explore what more we can do in pharmacy not least given the pressures on GP and the opportunity to look at what it is currently people go to GPS for where potentially the risk to do more at the pharmacy and we're already doing that."

Dry eye syndrome is incredibly common and prevalence is increasing globally. Studies show that prevalence rates vary from five to 50 per cent but can be as high as 75 per cent in people over the age of 40, in people who wear contact lenses and those who work with computers. It is more common in women than in men, particularly during and after the menopause. According to a new real-world research commissioned by world experts in eye-care, Rohto, more than eight in ten women (83 per cent) indicate that they suffer from the condition, but only once they have had the symptoms of dry eye syndrome described to them. Without detailed explanation, 56 per cent of people say they have never even heard of dry eye syndrome, showing just how under diagnosed it may be. Causes of dry eye Dry eyes are a clinical cause of eye irritation, fatigue, and discomfort, often causing feelings of itchiness, grittiness, and excess watering. If left untreated, dry eyes can even lead to long-term damage and sight problems. Dry eyes may occur if enough tears aren't produced if poor-quality tears are generated or if the tears evaporate from the surface of the eye too quickly. This leads to poor lubrication of the tear film. In a normal eye, the tear film4- the multilayer moist protective film - covers the cornea and lubricates the eye. However, if the lubricative process is faulty dry spots appear on the surface of the eye and this causes irritation and discomfort. The tear film has several layers: fatty oils, aqueous fluid, and mucus. This combination normally keeps the surface of your eyes lubricated, smooth and clear. But problems with any of these layers can cause dry eyes.

The Royal Pharmaceutical Society (RPS) has re-elected Andrew Carruthers as chair of RPS Scotland Pharmacy Board. Andrew is a Medicines Governance pharmacist within NHS Greater Glasgow and Clyde, where he has a clinical commitment to Care of the Elderly. Prior to becoming a pharmacist, he studied Pharmacology at the University of Glasgow, and maintains a keen interest in pharmacokinetics and research. In his address for the position, he said: "In my second term I want to continue to support and drive the introduction of RPS Ambassadors and the creation of an online RPS community." "As a previous RPS local coordinator, I've seen first-hand that RPS Local events are a great forum to formally support the training and development of local pharmacists. With input from our members and RPS staff we could share learning, inspire, and enable development, and build a supportive online community for the profession." He was the RPS Local Co-ordinator for Greater Glasgow and Clyde for 3 years, then he co-opted on to the Scottish Pharmacy Board (SPB) in 2018 and have been an active and effective member of the board. He was re-elected to the board in 2021 and he stood and was elected as Chair.

Dentistry is one of the most important yet underappreciated professions in the world. Without dental professionals, our teeth would fall out, we wouldn't be able to eat correctly, and our overall health would suffer. That's why ensuring you're doing everything possible to succeed in dentistry is crucial. And one of the best ways to do that is to listen to the advice of those who have come before you. If you are looking for some great tips on how to make it in the world of dentistry, then you have come to the right place. Here are four pieces of advice that will help you succeed. ATTEND A REPUTABLE DENTISTRY SCHOOL To be a great dentist, you must start with an excellent education. And that means attending a reputable dentistry school. There are many different schools, so it's essential to do your research and find one that is right for you, and this article gives an example of a dentistry course program overview. Consider things like accreditation, curriculum, clinical experience, and more when deciding. Additionally, it's important to note that you don't necessarily need to attend the most expensive school to get an excellent education. There are many affordable schools out there that can provide you with everything you need to succeed.

The world's first human challenge trial in which volunteers were deliberately exposed to Covid-19 to advance research into the disease was found to be safe in healthy young adults, one of the companies running the study said on Wednesday. The data supports the safety of this model which could theoretically provide a "plug and play" platform for testing therapies and vaccines using the original Covid-19 strain as well as variants of the virus, Open Orphan, which carried out the study, said in a statement. Open Orphan is running the project, launched a year ago, with Imperial College London, the UK government's vaccines task force and the clinical company  hVIVO. The trial infected 36 healthy male and female volunteers aged 18-29 years with the original SARS-CoV-2 strain of the virus and closely monitored them in a controlled quarantined setting. They will be followed up for 12 months after discharge from the quarantine facility.